| Gene symbol | CD5 | Synonyms | LEU1, T1 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | CD5 molecule | ||||
| Gene symbol | CD7 | Synonyms | GP40, LEU-9, TP41, Tp40 | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q25.3 | dbXrefs | |
| Description | CD7 molecule | ||||
| GTO ID | GTC3883 |
| Trial ID | NCT06420076 |
| Disease | T Cell Lymphoma | T-Cell Acute Lymphoblastic Leukemia |
| Altered gene | CD5|CD7 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD5/CD7 CAR-T |
| Co-treatment | chemotherapy |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | This is an Open, Single-arm, Clinical Study to Evaluate the Efficacy and Safety of Anti-CD7/CD5 CAR-T Cells in the Treatment of Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL), ETP-ALL, and Lymphoblastic Lymphoma (TLBL). |
| Year | 2024 |
| Country | China |
| Company sponsor | Essen Biotech |
| Other ID(s) | ESBI202496 |
| Cohort 1 | |||||||||
|
|||||||||